PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1084350
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1084350
Acute Otitis Media Treatment Market, by Drug Type, Formulation, End User, and Region - Global Trends, and Forecast, 2022 - 2028
Acute otitis media (AOM) is inflammation of the fluid in the middle ear. AOM is the most common infection and mainly caused in children under the age of 7 years. According to an article published American Family Physician Journal in 2013, around 80% of children will have at least one episode of acute otitis media (AOM) before their school age. AOM is mainly caused by bacteria such as Streptococcus pneumoniae (strep) and Hemophilus influenzae (H. flu) and viruses. Bacteria account for 85% cases of AOM and viruses account for only 15%. AOM is mostly treated with antibiotics usually for 7–10 days and with some analgesic and anesthetic in order to the reduce pain.
Market Dynamics
Increasing prevalence of acute otitis media is expected to be a major driver for growth of the market. Acute otitis media is a very common disease and occurs mostly in children, therefore, increasing prevalence of this disease is expected to increase demand for treatment drugs, thereby positively affecting market growth. According to an article published in The Journal of Laryngology & Otology, in 2013, prevalence of otitis media subtypes is between 7.1–12.8%. Furthermore, recent launches and FDA approvals for new drugs for the treatment of acute otitis media is also expected to drive the market growth in the near future. For instance, in 2015, Otonomy, Inc. received U.S. Food and Drug Administration (FDA) approval for its OTIPRIO (ciprofloxacin otic suspension) indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement. In 2021, Otonomy, Inc. launched OTIPRIO in U.S. market.
Key features of the study:
This report provides in-depth analysis of acute otitis media treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global acute otitis media treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Pfizer, Inc., Eli Lilly and Company, Abbott Laboratories, GlaxoSmithKline plc., Bayer AG, Novartis AG, Pediapharm Inc., Sanofi S.A., and Bristol Myers Squibb Company.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global acute otitis media treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the acute otitis media treatment market
Detailed Segmentation:
Global Acute Otitis Media Treatment Market, By Drug Type :
Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic
Global Acute Otitis Media Treatment Market, By Formulation:
Oral
Topical
Global Acute Otitis Media Treatment Market, By Distribution Channel:
Hospital
Retail pharmacies
Online pharmacies
Global Acute Otitis Media Treatment Market, By Geography:
North America
By Drug Type :
Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic
By Formulation
Oral
Topical
By Distribution Channel:
Hospital
Retail pharmacies
Online pharmacies
By Country:
U.S.
Canada
Europe
By Drug Type :
Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic
By Formulation
Oral
Topical
By Distribution Channel:
Hospital
Retail pharmacies
Online pharmacies
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type :
Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic
By Formulation
Oral
Topical
By Distribution Channel:
Hospital
Retail pharmacies
Online pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Drug Type :
Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic
By Formulation
Oral
Topical
By Distribution Channel:
Hospital
Retail pharmacies
Online pharmacies
By Country:
Brazil
Mexico
Rest of Latin America
Middle East
By Drug Type :
Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic
By Formulation
Oral
Topical
By Distribution Channel:
Hospital
Retail pharmacies
Online pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Type :
Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic
By Formulation
Oral
Topical
By Distribution Channel:
Hospital
Retail pharmacies
Online pharmacies
By Country:
Central Africa
South Africa
North Africa
Company Profiles
Pfizer, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Eli Lilly and Company
Abbott Laboratories
GlaxoSmithKline plc.
Bayer AG
Novartis AG
Pediapharm Inc.
Sanofi S.A.
Bristol Myers Squibb Company
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Formulation
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Technological Trends
- Unmet Needs
- Regulatory Scenario
- Recent Product Approvals/Launch
- Technological Advancement
- PEST Analysis
- Porter's Five Forces Analysis
4. Global Acute Otitis Media Treatment Market, By Drug Type, 2017 - 2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Nonsteroidal anti-Inflammatory drug
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Analgesic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Anaesthetic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
5. Global Acute Otitis Media Treatment Market, By Formulation, 2017 - 2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
6. Global Acute Otitis Media Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
7. Global Acute Otitis Media Treatment Market, By Region, 2017 - 2028 (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- North America
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of APAC
- Latin America
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Central Africa
- South Africa
- North Africa
- Middle East
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
8. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pediapharm Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Section
- References
- Research Methodology
- About us and Sales Contact
